|drug1679||Intravenous Immune Globulin Wiki||1.00|
|drug3121||Standard Medical Treatment Wiki||0.45|
There is one clinical trial.
Methods: Out of 2000 kidney transplant recipients in our center in Kuwait, collecting data was started for all COVID-19-positive kidney transplant recipients till August 2020. Clinical features, management details and both patient and graft outcomes were reported.
Description: living patients (1), dead patients(2) during the study periodMeasure: patient outcome Time: 30 days
Description: functioning graft(1), failed graft(2) and impaired graft(3) at the end of the studyMeasure: Kidney graft outcome Time: 30 days
Description: Diabetes(=!), IHD(=1), Hypertension(=1),pulmonary diseases(=1)Measure: risk factors for getting COVID19 infection Time: 30 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports